Pds Biotechnology Corp (PDSB) Stock Price & Analysis
Pds Biotechnology Corp (PDSB) rose 3.00% to USD 1.03 as of June 10, 2026 at 06:44 UTC, according to Nexqual real-time market data.
PDSB last closed at USD 1; the session ranged USD 0.96–1.04 on volume of 899,985 shares. Market capitalization is $57.49M, with a 52-week range of USD 0.51–1.92 (NCM). Source: Nexqual, June 10, 2026 at 06:44 UTC.
Key Statistics (as of June 10, 2026 at 06:44 UTC)
| Price | USD 1.03 |
|---|---|
| Change | ▲ 3.00% (up) |
| Previous Close | USD 1 |
| Open | USD 1.01 |
| Day Range | USD 0.96 – 1.04 |
| 52-Week Range | USD 0.51 – 1.92 |
| Volume | 899,985 shares |
| Market Cap | $57.49M |
| Exchange | NCM |
Technical Analysis (PDSB)
Nexqual's technical model rates PDSB "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 06:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.07 (neutral) |
| vs SMA50 | Below (USD 1.06) |
| MACD | -0 (negative) |
Analyst Ratings (PDSB)
Wall Street analysts rate PDSB "None" based on 3 analysts, with a mean price target of USD 7.5 (range USD 3–15), per Nexqual as of June 10, 2026 at 06:44 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 7.5 |
| High Target | USD 15 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (PDSB)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.13 vs est -0.14 ▲ beat |
| 2025-12-31 | USD -0.14 vs est -0.2 ▲ beat |
| 2025-09-30 | USD -0.19 vs est -0.2 ▲ beat |
| 2025-06-30 | USD -0.21 vs est -0.23 ▲ beat |
Source: Nexqual, June 10, 2026 at 06:44 UTC.
Financials & Fundamentals (PDSB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 182.94 |
| Total Cash | $26.71M |
| Total Debt | $16.93M |
Source: Nexqual, June 10, 2026 at 06:44 UTC.
Financial Health Score (PDSB)
Nexqual rates Pds Biotechnology Corp's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 06:44 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $27M cash vs $17M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (PDSB)
| Insider Ownership | +1.51% |
|---|---|
| Institutional Ownership | +9.16% |
| Shares Outstanding | 55.82M |
| Float | 54.40M |
| Short % of Float | +3.26% |
Source: Nexqual, June 10, 2026 at 06:44 UTC.
Leadership (PDSB)
Pds Biotechnology Corp is led by Frank K. Bedu-Addo (age 59), President, CEO & Director, per Nexqual as of June 10, 2026 at 06:44 UTC.
| President, CEO & Director | Frank K. Bedu-Addo (age 59) |
|---|---|
| Chief Operating Officer | Stephan Toutain M.B.A., M.S. (age 59) |
| Principal Financial & Accounting Officer and CFO | Lars Robert Boesgaard (age 55) |
| Chief Scientific Officer | Gregory L. Conn (age 69) |
Major Backers & Investors (PDSB)
Notable institutional backers of Pds Biotechnology Corp include Fidelity, BLAIR WILLIAM & CO/IL, Renaissance Technologies, according to Nexqual as of June 10, 2026 at 06:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.12% |
| BLAIR WILLIAM & CO/IL | 0.54% |
| Renaissance Technologies | 0.4% |
| Inspirion Wealth Advisors LLC | 0.33% |
| Armistice Capital, LLC | 0.31% |
| Wells Fargo & Company | 0.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.39% |
| BlackRock | 1.2% |
| Geode Capital | 1.18% |
| State Street | 0.24% |
Source: Nexqual, June 10, 2026 at 06:44 UTC.
From Pds Biotechnology Corp's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States.
- The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
- It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers.
- In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MREO | Mereo BioPharma Group plc | USD 0.31 | ▼ 2.24% |
| PAVM | PAVmed Inc. | USD 4.68 | ▼ 14.13% |
| DCOY | Decoy Therapeutics Inc. | USD 5.51 | ▼ 16.64% |
| CRVS | Corvus Pharmaceuticals, Inc. | USD 11.17 | ▲ 0.45% |
| CYPH | Cypherpunk Technologies Inc. | USD 0.68 | ▲ 30.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:44 UTC. This page is informational and not investment advice.